WAVE Life Sciences Ltd. (WVE) saw its stock price surge 5.06% during intraday trading on Thursday. The significant upward movement followed the company's release of its fourth quarter and full year 2025 financial results and a detailed business update earlier in the session.

The biotechnology firm reported Q4 revenue of $17.244 million, surpassing the analyst consensus estimate of $16.3 million. Investors responded positively to updates on the company's RNA medicines pipeline, including promising interim results for its obesity treatment candidate WVE-007, which showed fat loss comparable to GLP-1 drugs with the added benefit of muscle preservation. Additionally, the company reported advancements for WVE-006 toward potential accelerated approval for alpha-1 antitrypsin deficiency (AATD) and progress on WVE-008 for liver disease.

Further supporting investor confidence was the announcement that WAVE Life Sciences is well capitalized with $602.1 million in cash and cash equivalents as of December 31, 2025, providing an expected cash runway into the third quarter of 2028. Analyst sentiment remains bullish, with the current average rating at "buy" and a median 12-month price target of $32.50, representing significant upside potential from recent levels.